114 related articles for article (PubMed ID: 25946562)
1. Utilizing 19F NMR to investigate drug disposition early in drug discovery.
Hu H; Huang N; Yi P; Hui YH; Dally RD; Ehlhardt WJ; Kulanthaivel P
Xenobiotica; 2015; 45(12):1081-91. PubMed ID: 25946562
[TBL] [Abstract][Full Text] [Related]
2. Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies.
Mutlib A; Espina R; Atherton J; Wang J; Talaat R; Scatina J; Chandrasekaran A
Chem Res Toxicol; 2012 Mar; 25(3):572-83. PubMed ID: 22292524
[TBL] [Abstract][Full Text] [Related]
3. Comparison between Radioanalysis and
Hu H; Katyayan KK; Czeskis BA; Perkins EJ; Kulanthaivel P
Drug Metab Dispos; 2017 Apr; 45(4):399-408. PubMed ID: 28188298
[TBL] [Abstract][Full Text] [Related]
4. HPLC-NMR with severe column overloading: fast-track metabolite identification in urine and bile samples from rat and dog treated with [14C]-ZD6126.
Lenz EM; D'Souza RA; Jordan AC; King CD; Smith SM; Phillips PJ; McCormick AD; Roberts DW
J Pharm Biomed Anal; 2007 Feb; 43(3):1065-77. PubMed ID: 17030109
[TBL] [Abstract][Full Text] [Related]
5. Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-NMR spectroscopy.
Monteagudo E; Pesci S; Taliani M; Fiore F; Petrocchi A; Nizi E; Rowley M; Laufer R; Summa V
Xenobiotica; 2007 Sep; 37(9):1000-12. PubMed ID: 17896326
[TBL] [Abstract][Full Text] [Related]
6. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
[TBL] [Abstract][Full Text] [Related]
8. In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy.
Barbuch RJ; Campanale K; Hadden CE; Zmijewski M; Yi P; O'Bannon DD; Burkey JL; Kulanthaivel P
Drug Metab Dispos; 2006 Feb; 34(2):213-24. PubMed ID: 16258078
[TBL] [Abstract][Full Text] [Related]
9. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide.
Kurebayashi H; Betsui H; Ohno Y
Toxicol Sci; 2003 May; 73(1):17-25. PubMed ID: 12700409
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
11. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
13. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Mamidi RN; Cuyckens F; Chen J; Scheers E; Kalamaridis D; Lin R; Silva J; Sha S; Evans DC; Kelley MF; Devineni D; Johnson MD; Lim HK
Drug Metab Dispos; 2014 May; 42(5):903-16. PubMed ID: 24568888
[TBL] [Abstract][Full Text] [Related]
15. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.
Waters NJ; Smith SA; Olhava EJ; Duncan KW; Burton RD; O'Neill J; Rodrigue ME; Pollock RM; Moyer MP; Chesworth R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):43-62. PubMed ID: 26645404
[TBL] [Abstract][Full Text] [Related]
17. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
18. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.
Balani SK; Woolf EJ; Hoagland VL; Sturgill MG; Deutsch PJ; Yeh KC; Lin JH
Drug Metab Dispos; 1996 Dec; 24(12):1389-94. PubMed ID: 8971147
[TBL] [Abstract][Full Text] [Related]
19. Physiological disposition of L-663,581, a partial agonist of the benzodiazepine receptor, in laboratory animals.
Chen IW; Lin JH
Drug Metab Dispos; 1994; 22(5):693-9. PubMed ID: 7835219
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys.
Emary WB; Toren PC; Mathews B; Huh K
Drug Metab Dispos; 1998 Aug; 26(8):725-31. PubMed ID: 9698285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
